High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications
The session will provide practical insights for pathologists, molecular biologists, and laboratory professionals interested in applying digital PCR technologies for ESR1 research and assay workflow optimization.
Clinical Scorecard: High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications
At a Glance
Category
Detail
Condition
Metastatic Breast Cancer
Key Mechanisms
ESR1 mutations as a mechanism of acquired resistance to endocrine therapy
Target Population
Patients with HR-positive/HER2-negative metastatic breast cancer
Care Setting
Research settings
Key Highlights
ESR1 mutations are clinically actionable biomarkers in metastatic breast cancer.
Digital PCR (dPCR) offers high sensitivity for detecting low-frequency ESR1 mutations.
Liquid biopsy is essential for guiding treatment decisions and monitoring disease evolution.
Cross-laboratory reproducibility of dPCR-based ESR1 testing has been demonstrated.
Assay validation and quality assurance are critical for high-sensitivity ctDNA analysis.
Guideline-Based Recommendations
Diagnosis
ESR1 testing is recommended for assessing resistance to endocrine therapy.
Management
Liquid biopsy should be considered for monitoring treatment response.
Monitoring & Follow-up
ctDNA analysis can provide insights into disease evolution.
Risks
The content is for research use only and not for diagnostic procedures.
Patient & Prescribing Data
Patients with HR-positive/HER2-negative metastatic breast cancer undergoing endocrine therapy.
ESR1 mutations can inform treatment decisions.
Clinical Best Practices
Implement robust assay validation and quality assurance for dPCR.
Utilize digital PCR for high-sensitivity ctDNA analysis in research.
Advances in biosensors and manufacturing could bring continuous molecular monitoring into routine care, but clinical validation remains a major challenge
